CY
CYL.F CryoLife Inc
- Market cap
- EUR 898M
- P/E
- -
- P/B
- 2.21x
- ROE
- -6.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is CYL.F undervalued?
Graham numberThe Graham number of CryoLife Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CryoLife Inc fundamental analysis
No fundamental analysis for CryoLife Inc yet.
CryoLife Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CryoLife Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides…
Full company profileCryoLife Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
CryoLife Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 180M | 190M | 263M | 276M | 253M | 299M | 314M | 354M | 389M | 441M | 488M |
| Gross Profit | 119M | 129M | 173M | 183M | 168M | 198M | 203M | 229M | 249M | 284M | 309M |
| Operating Income | 13.9M | 7.97M | 9.31M | 17.0M | 2.44M | -7.81M | 6.20M | -8.51M | 38.9M | 26.7M | 493K |
| EBITDA | - | 18.2M | 27.5M | 34.8M | 20.2M | 26.0M | 25.7M | 26.8M | 51.0M | 63.8M | 32.4M |
| Net Income | 10.8M | 3.70M | -2.84M | 1.72M | -16.7M | -14.8M | -19.2M | -30.7M | -13.4M | 9.77M | -26.7M |
| EPS | - | 0.10 | -0.08 | 0.05 | -0.43 | -0.37 | -0.48 | -0.75 | -0.32 | 0.20 | -0.55 |
| Balance Sheet | |||||||||||
| Total Assets | 316M | 590M | 571M | 606M | 789M | 793M | 763M | 792M | 789M | 885M | 1.04B |
| Total Liabilities | 107M | 313M | 296M | 320M | 461M | 492M | 478M | 511M | 513M | 437M | 596M |
| Shareholders' Equity | 209M | 277M | 275M | 286M | 329M | 301M | 284M | 282M | 276M | 448M | 446M |
| Cash & Short-term Investments | 56.6M | 40.0M | 41.5M | 33.8M | 62.0M | 55.0M | 39.4M | 58.9M | 53.5M | 64.9M | 48.4M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 19.7M | 10.8M | 9.88M | 15.8M | 12.4M | -2.59M | -5.15M | 7.77M | 22.2M | 39.9M | -6.22M |
| Capital Expenditure | 7.42M | 6.63M | 5.79M | 8.07M | 7.33M | 13.1M | 9.02M | 9.29M | 11.2M | 39.0M | 42.4M |
| Free Cash Flow | - | 3.76M | 4.10M | 7.76M | 5.04M | -15.7M | -15.9M | -1.52M | 11.0M | 839K | -48.6M |
| Ratios | |||||||||||
| ROE | 5.2% | 1.3% | -1.0% | 0.6% | -5.1% | -4.9% | -6.7% | -10.9% | -4.8% | 2.2% | -6.0% |
| ROA | 3.4% | 0.6% | -0.5% | 0.3% | -2.1% | -1.9% | -2.5% | -3.9% | -1.7% | 1.1% | -2.6% |
| Net Profit Margin | 6.0% | 2.0% | -1.1% | 0.6% | -6.6% | -5.0% | -6.1% | -8.7% | -3.4% | 2.2% | -5.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
CryoLife Inc dividends
CryoLife Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 3:2 on Dec 28, 2000.
Who owns CryoLife Inc
- Insiders 4.28%
- Institutions 95.61%
- Public & others 0.11%
- Shares outstanding 48.8M
- Free float 46.4M
CryoLife Inc company profile
- Company name
- CryoLife Inc
- Ticker
- CYL.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 1,800
- Fiscal year end
- December
- Address
- 1655 Roberts Boulevard NW, Kennesaw, GA, United States, 30144
- Phone
- 770 419 3355
- Website
- artivion.com
About CryoLife Inc
Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers On-X prosthetic aortic and mitral heart valves; On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters; Chord-X ePTFE sutures; pyrolytic carbon coating services; E-vita Open NEO, a hybrid stent graft; Arcevo, an LSA hybrid stent graft system; AMDS hybrid prosthesis; and NEXUS ONE, an endovascular stent graft system. It also provides NEXUS DUO, an aortic arch system; NEXUS TRE, a custom-made three branch graft; E-vita thoracic 3G, a stent graft system; E-xtra Design Engineering, a range of stent graft systems for the treatment of aortic vascular diseases, such as TAAA and Artivex; E-nside, a multibranch stent graft system; E-tegra, an AAA stent graft system; E-ventus BX and Tuva BX balloon-expandable peripheral stent grafts; and E-liac, a stent graft used to treat aneurysmal iliac arteries. In addition, the company offers synthetic vascular grafts that are used in open aortic and peripheral vascular surgical procedures; BioGlue, a surgical sealant; CryoValve SG pulmonary heart valve; CryoPatch SG pulmonary cardiac patch; SynerGraft, a decellularization technology; vascular preservation services; and PhotoFix, a bovine pericardial patch fixated. It markets its products and preservation services primarily to physicians through a direct sales team to hospitals and other healthcare facilities. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.
CryoLife Inc management
10- Mr. James Patrick MackinChairman, President & CEO · born 1967
- Mr. Lance A. Berry CPAEVP, COO, CFO & Treasurer · born 1972
- Ms. Jean F. Holloway Esq.Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary · born 1957
- Mr. John E. DavisSenior VP & Chief Commercial Officer · born 1965
- Ms. Amy D. Horton CPAVP & Chief Accounting Officer · born 1970
- Mr. Matthew A. GetzVP of Human Resources & Chief Human Resources Officer · born 1969
- Mr. Jason D. AsperSenior VP and Chief Strategy & Digital Officer · born 1976
- Mr. Andrew M. GreenSenior Vice President of Regulatory & Quality · born 1969
- Dr. Simona Zannetti M.D.Senior Vice President of Clinical Research & Chief Medical Officer
- Dr. Robert C. Thomson Ph.D.Vice President of Research & Development · born 1971